Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
HLX07 is a humanized monoclonal antibody directed against EGFR, which was demonstarted to have increased affinty for Egfr as compared to cetuximab (JCO.2017.35.15_suppl.e14078).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HLX07||HLX-07|HLX 07|Pimurutamab||EGFR Antibody 38||HLX07 (pimurutamab) is a humanized monoclonal antibody directed against EGFR, which was demonstrated to have increased affinity for Egfr compared to cetuximab and may result in antitumor activity (PMID: 33713216).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02648490||Phase I||Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07||An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers||Completed||USA||1|